Etesevimab Biosimilar - Research Grade

Out of stock

Only %1 left

SKU

ICH5535-10mg

Add to Compare

Be the first to review this product

Etesevimab Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>90% by SDS-PAGE

Species Reactivity

Human

Target

Severe acute respiratory syndrome coronavirus 2

Concentration

>1mg/ml

Isotype

IgG1 - kappa

Host

CHO Cells

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Shipping Conditions

Blue ice

Background

This product is a research-grade biosimilar of etesevimab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is not the clinical drug and is not intended for diagnostic or therapeutic application. The molecule is built around the antigen recognized by etesevimab, a human IgG1 kappa neutralizing monoclonal antibody directed against the SARS-CoV-2 spike glycoprotein. The originator was developed as a passive-immunization agent for COV-19 and was used clinically in combination with bamlanivimab. As a biosimilar analog, this reagent reproduces the binding specificity of the originator so investigators can study spike engagement, receptor-blocking, and neutralization mechanisms in controlled in-vitro systems. It is offered at research grade with low endotoxin, in bulk milligram to gram quantities suitable for assay development, standardization, and comparator work. Because the target is a viral antigen rather than a host protein, the reagent is primarily used in functional and binding assays rather than for dosing animals. All characterization and application decisions remain the responsibility of the investigator. The target of etesevimab is the spike (S) glycoprotein of SARS-CoV-2, the surface trimer that mediates viral entry. Etesevimab binds an epitope within the receptor-binding domain (RBD) of the S1 subunit, the region that engages the host receptor ACE2. By occupying this interface, the antibody sterically blocks the RBD-ACE2 interaction and thereby prevents attachment and membrane fusion, neutralizing infectivity. The RBD is a key determinant of tropism and a dominant target of the neutralizing antibody response, which also makes it a hotspot for immune-escape mutations that arise across viral variants. Because the antigen is a viral protein and not a human host molecule, biosimilar analogs of anti-spike antibodies are used to interrogate viral biology, epitope accessibility, and neutralization rather than to modulate host pathways.

Purification Method

This monoclonal antibody was purified using Protein A

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Storage

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use

Products are for research use only. Not for use in diagnostic or therapeutic procedures.